WHO 2022 landscape of papillary and chromophobe renal cell carcinoma

Lobo J, Ohashi R, Amin MB, Berney DM, Compérat EM, Cree IA, Gill AJ, Hartmann A, Menon S, Netto GJ, Raspollini MR, Rubin MA, Tan PH, Tickoo SK, Tsuzuki T, Turajlic S, Zhou M, Srigley JR, Moch H (2022)

Publication Type: Journal article, Review article

Publication year: 2022

Journal

DOI: 10.1111/his.14700

Abstract

The 5th edition of the WHO Classification of Tumours of the Urinary and Male Genital Systems contains relevant revisions and introduces a group of molecularly defined renal tumour subtypes. Herein we present the World Health Organization (WHO) 2022 perspectives on papillary and chromophobe renal cell carcinoma with emphasis on their evolving classification, differential diagnosis, and emerging entities. The WHO 2022 classification eliminated the type 1/2 papillary renal cell carcinoma (pRCC) subcategorization, given the recognition of frequent mixed tumour phenotypes and the existence of entities with a different molecular background within the type 2 pRCC category. Additionally, emerging entities such as biphasic squamoid alveolar RCC, biphasic hyalinising psammomatous RCC, papillary renal neoplasm with reverse polarity, and Warthin-like pRCC are included as part of the pRCC spectrum, while additional morphological and molecular data are being gathered. In addition to oncocytomas and chromophobe renal cell carcinoma (chRCC), a category of ‘other oncocytic tumours’ with oncocytoma/chRCC-like features has been introduced, including emerging entities, most with TSC/mTOR pathway alterations (eosinophilic vacuolated tumour and so-called ‘low-grade’ oncocytic tumour), deserving additional research. Eosinophilic solid and cystic RCC was accepted as a new and independent tumour entity. Finally, a highly reproducible and clinically relevant universal grading system for chRCC is still missing and is another niche of ongoing investigation. This review discusses these developments and highlights emerging morphological and molecular data relevant for the classification of renal cell carcinoma.

Authors with CRIS profile

Involved external institutions

Universitätsspital Zürich (USZ) Switzerland (CH) Instituto Português de Oncologia do Porto FG, EPE (IPO-Porto) Portugal (PT) The University of Tennessee Health Science Center United States (USA) (US) Queen Mary, University of London United Kingdom (GB) Sorbonne Université France (FR) International Agency for Research on Cancer (IARC) France (FR) University of Sydney (USYD) Australia (AU) Tata Memorial Hospital India (IN) University of Alabama at Birmingham (UAB) United States (USA) (US) Careggi University Hospital / Azienda Ospedaliero Universitaria Careggi Italy (IT) Weill Cornell Medicine United States (USA) (US) Singapore General Hospital Singapore (SG) Memorial Sloan Kettering Cancer Center United States (USA) (US) Aichi Medical University Hospital / 愛知医科大学病院 Japan (JP) Royal Marsden Hospital / The Royal Marsden NHS Foundation Trust United Kingdom (GB) Tufts Medical Center United States (USA) (US) University of Toronto Canada (CA)

How to cite

APA:

Lobo, J., Ohashi, R., Amin, M.B., Berney, D.M., Compérat, E.M., Cree, I.A.,... Moch, H. (2022). WHO 2022 landscape of papillary and chromophobe renal cell carcinoma. Histopathology. https://dx.doi.org/10.1111/his.14700

MLA:

Lobo, João, et al. "WHO 2022 landscape of papillary and chromophobe renal cell carcinoma." Histopathology (2022).

BibTeX: Download